{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:58:30Z","timestamp":1785513510757,"version":"3.56.0"},"reference-count":60,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Arthralgia is a frequent but often overlooked symptom in patients with psoriasis (PsO) and may represent an early manifestation of psoriatic arthritis (PsA). Objective: To provide a practical overview aiming to support dermatologists in the identification and management of arthralgia in PsO. Methods: An expert panel comprising three dermatologists and two rheumatologists convened to discuss data from a literature search of PubMed\/MEDLINE and EMBASE conducted using the terms \u201carthralgia\u201d and \u201cpsoriasis.\u201d Relevant studies were qualitatively analyzed based on clinical relevance and available data on epidemiology, pathophysiology, diagnosis, and management. Results: Predictors of PsA development and distinctions between inflammatory and noninflammatory joint pain are presented, and the main differential diagnoses such as osteoarthritis and fibromyalgia are discussed. The importance of validated screening tools, early imaging, and timely rheumatology referral is emphasized, along with recommendations for patient education and risk factor management. Conclusions: Dermatologists play a central role in the early detection of arthralgia in patients with PsO. Timely rheumatology referral is essential to facilitating early intervention, preventing irreversible joint damage, and improving long-term outcomes.<\/jats:p>","DOI":"10.5826\/dpc.1603a7416","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:43Z","timestamp":1785510523000},"page":"7416","source":"Crossref","is-referenced-by-count":0,"title":["Arthralgia in Patients with Chronic Plaque Psoriasis: Practical Insights for Dermatologists"],"prefix":"10.5826","volume":"16","author":[{"given":"Paolo","family":"Gisondi","sequence":"first","affiliation":[{"name":"Verona University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellinato","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Errichetti","sequence":"first","affiliation":[{"name":"Institute of Dermatology, \"Santa Maria della Misericordia\" University Hospital, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"first","affiliation":[{"name":"Section of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"first","affiliation":[{"name":"Department of Medical and Biological Sciences, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"10.5826\/dpc.1603a7416_ref1","doi-asserted-by":"crossref","unstructured":"Faustini F, Simon D, Oliveira I, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016;75(12):2068\u20132074. DOI:10.1136\/annrheumdis-2015-208821","DOI":"10.1136\/annrheumdis-2015-208821"},{"key":"10.5826\/dpc.1603a7416_ref2","doi-asserted-by":"crossref","unstructured":"Haberman R, Perez-Chada LM, Merola JF, et al. Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. Curr Rheumatol Rep. 2018;20(12):76. DOI:10.1007\/s11926-018-0785-6","DOI":"10.1007\/s11926-018-0785-6"},{"key":"10.5826\/dpc.1603a7416_ref3","doi-asserted-by":"crossref","unstructured":"Gisondi P, Bellinato F, Maurelli M, et al. Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis. Psoriasis (Auckl). 2022;12:213\u2013220. DOI:10.2147\/PTT.S323300","DOI":"10.2147\/PTT.S323300"},{"key":"10.5826\/dpc.1603a7416_ref4","doi-asserted-by":"crossref","unstructured":"Pennington SR, FitzGerald O. Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis. Front Med (Lausanne). 2021;8:723944. DOI:10.3389\/fmed.2021.723944","DOI":"10.3389\/fmed.2021.723944"},{"key":"10.5826\/dpc.1603a7416_ref5","doi-asserted-by":"crossref","unstructured":"van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):491\u2013496. DOI:10.1136\/annrheumdis-2016-209846","DOI":"10.1136\/annrheumdis-2016-209846"},{"key":"10.5826\/dpc.1603a7416_ref6","doi-asserted-by":"crossref","unstructured":"Floris A, Mugheddu C, Sichi L, et al. The Challenging Differentiation of Psoriatic Arthritis from Other Arthropathies and Nonspecific Arthralgias in Patients with Psoriasis: Results of a Cross-Sectional Rheumatologic Assessment of a Large Dermatologic Cohort. J Clin Med. 2023;12(18):6090. DOI:10.3390\/jcm12186090","DOI":"10.3390\/jcm12186090"},{"key":"10.5826\/dpc.1603a7416_ref7","doi-asserted-by":"crossref","unstructured":"Eder L, Polachek A, Rosen CF, et al. The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. Arthritis Rheumatol. 2017;69(3):622\u2013629. DOI:10.1002\/art.39973","DOI":"10.1002\/art.39973"},{"key":"10.5826\/dpc.1603a7416_ref8","doi-asserted-by":"crossref","unstructured":"Zabotti A, Fagni F, Gossec L, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10(2)10. DOI:1136\/rmdopen-2024-004314","DOI":"10.1136\/rmdopen-2024-004314"},{"key":"10.5826\/dpc.1603a7416_ref9","doi-asserted-by":"crossref","unstructured":"Eder L, Lee KA, Chandran V, et al. Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention. Arthritis Rheumatol. 2025;77(6):686\u2013695. DOI:10.1002\/art.42661","DOI":"10.1002\/art.42661"},{"key":"10.5826\/dpc.1603a7416_ref10","doi-asserted-by":"crossref","unstructured":"Lindberg I, Lilja M, Geale K, et al. Incidence of Psoriatic Arthritis in Patients with Skin Psoriasis and Associated Risk Factors: A Retrospective Population-based Cohort Study in Swedish Routine Clinical Care. Acta Derm Venereol. 2020;100(18):adv00324. DOI:10.2340\/00015555-3682","DOI":"10.2340\/00015555-3682"},{"key":"10.5826\/dpc.1603a7416_ref11","doi-asserted-by":"crossref","unstructured":"van Steenbergen HW, van Nies JA, Huizinga TW, et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Ann Rheum Dis. 2015;74(6):1225\u201332. DOI:10.1136\/annrheumdis-2014-205522","DOI":"10.1136\/annrheumdis-2014-205522"},{"key":"10.5826\/dpc.1603a7416_ref12","doi-asserted-by":"crossref","unstructured":"Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u20131170. DOI:10.1136\/ard-2023-224148","DOI":"10.1136\/ard-2023-224148"},{"key":"10.5826\/dpc.1603a7416_ref13","doi-asserted-by":"crossref","unstructured":"Green A, Tillett W, McHugh N, Smith T, Group PS. Using Bayesian networks to identify musculoskeletal symptoms influencing the risk of developing psoriatic arthritis in people with psoriasis. Rheumatology (Oxford). 2022;61(2):581\u2013590. DOI:10.1093\/rheumatology\/keab310","DOI":"10.1093\/rheumatology\/keab310"},{"key":"10.5826\/dpc.1603a7416_ref14","doi-asserted-by":"crossref","unstructured":"Zabotti A, De Lucia O, Sakellariou G, et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther. 2021;8(4):1519\u20131534. DOI:10.1007\/s40744-021-00378-w","DOI":"10.1007\/s40744-021-00378-w"},{"key":"10.5826\/dpc.1603a7416_ref15","doi-asserted-by":"crossref","unstructured":"Garcia-Salinas R, Magri S, Mareco J, et al. Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors. Rheumatology (Oxford). 2025;64(5):2550\u20132556. DOI:10.1093\/rheumatology\/keae562","DOI":"10.1093\/rheumatology\/keae562"},{"key":"10.5826\/dpc.1603a7416_ref16","doi-asserted-by":"crossref","unstructured":"Zabotti A, McGonagle DG, Giovannini I, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5(2):e001067. DOI:10.1136\/rmdopen-2019-001067","DOI":"10.1136\/rmdopen-2019-001067"},{"key":"10.5826\/dpc.1603a7416_ref17","doi-asserted-by":"crossref","unstructured":"Simon D, Tascilar K, Kleyer A, et al. Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis Rheumatol. 2022;74(2):253\u2013262. DOI:10.1002\/art.41239","DOI":"10.1002\/art.41239"},{"key":"10.5826\/dpc.1603a7416_ref18","doi-asserted-by":"crossref","unstructured":"De Marco G, Zabotti A, Baraliakos X, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143. DOI:10.1136\/rmdopen-2023-003143","DOI":"10.1136\/rmdopen-2023-003143"},{"key":"10.5826\/dpc.1603a7416_ref19","doi-asserted-by":"crossref","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334. DOI:10.1136\/ard-2022-223296","DOI":"10.1136\/ard-2023-223937"},{"key":"10.5826\/dpc.1603a7416_ref20","doi-asserted-by":"crossref","unstructured":"Patt YS, Watad A, Giovannini I, et al. Risk factors for psoriatic arthritis development in psoriasis patients: myths, pitfalls, and pearls. Clin Exp Rheumatol. 2024;42(9):1856\u20131866. DOI:10.55563\/clinexprheumatol\/h6176m","DOI":"10.55563\/clinexprheumatol\/h6176m"},{"key":"10.5826\/dpc.1603a7416_ref21","doi-asserted-by":"crossref","unstructured":"Gudu T, Ng B, Jethwa H, et al. Improving Imaging Modalities in Early Psoriatic Arthritis: The Role of Ultrasound in Early Diagnosis of Psoriatic Arthritis. Front Med (Lausanne). 2021;8:804695. DOI:10.3389\/fmed.2021.804695","DOI":"10.3389\/fmed.2021.804695"},{"key":"10.5826\/dpc.1603a7416_ref22","doi-asserted-by":"crossref","unstructured":"Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020;31(7):662\u2013679. DOI:10.1080\/09546634.2019.1605142","DOI":"10.1080\/09546634.2019.1605142"},{"key":"10.5826\/dpc.1603a7416_ref23","doi-asserted-by":"crossref","unstructured":"Gratacos J, Behrens F, Coates LC, et al. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. Joint Bone Spine. 2021;88(3):105175. DOI:10.1016\/j.jbspin.2021.105175","DOI":"10.1016\/j.jbspin.2021.105175"},{"key":"10.5826\/dpc.1603a7416_ref24","doi-asserted-by":"crossref","unstructured":"Tinazzi I, McGonagle D, Aydin SZ, et al. 'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. 2018;77(6):922\u2013925. DOI:10.1136\/annrheumdis-2017-212681","DOI":"10.1136\/annrheumdis-2017-212681"},{"key":"10.5826\/dpc.1603a7416_ref25","doi-asserted-by":"crossref","unstructured":"Schett G, Lories RJ, D'Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731\u2013741. DOI:10.1038\/nrrheum.2017.188","DOI":"10.1038\/nrrheum.2017.188"},{"key":"10.5826\/dpc.1603a7416_ref26","doi-asserted-by":"crossref","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. DOI:10.1002\/art.21972","DOI":"10.1002\/art.21972"},{"key":"10.5826\/dpc.1603a7416_ref27","doi-asserted-by":"crossref","unstructured":"Gisondi P, Altomare G, Ayala F, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol. 2018;32(4):515\u2013528. DOI:10.1111\/jdv.14741","DOI":"10.1111\/jdv.14741"},{"key":"10.5826\/dpc.1603a7416_ref28","doi-asserted-by":"crossref","unstructured":"Perez-Chada LM, Gottlieb AB, Cohen J, et al. Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. J Am Acad Dermatol. 2020;82(1):54\u201361. DOI:10.1016\/j.jaad.2019.05.075","DOI":"10.1016\/j.jaad.2019.05.075"},{"key":"10.5826\/dpc.1603a7416_ref29","doi-asserted-by":"crossref","unstructured":"Bellinato F, Gisondi P, Girolomoni G. A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2020;13(5):481\u2013491. DOI:10.1080\/17512433.2020.1759415","DOI":"10.1080\/17512433.2020.1759415"},{"key":"10.5826\/dpc.1603a7416_ref30","doi-asserted-by":"crossref","unstructured":"Soleymani T, Reddy SM, Cohen JM, Neimann AL. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. Curr Rheumatol Rep. 2017;20(1):1. DOI:10.1007\/s11926-017-0706-0","DOI":"10.1007\/s11926-017-0706-0"},{"key":"10.5826\/dpc.1603a7416_ref31","doi-asserted-by":"crossref","unstructured":"McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54(1):29\u201338. DOI:10.1093\/rheumatology\/keu328","DOI":"10.1093\/rheumatology\/keu328"},{"key":"10.5826\/dpc.1603a7416_ref32","doi-asserted-by":"crossref","unstructured":"Macchioni P, Salvarani C, Possemato N, et al. Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. J Rheumatol. 2019;46(8):904\u2013911. DOI:10.3899\/jrheum.171411","DOI":"10.3899\/jrheum.171411"},{"key":"10.5826\/dpc.1603a7416_ref33","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319\u2013329. DOI:10.1016\/j.semarthrit.2016.08.012","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"10.5826\/dpc.1603a7416_ref34","doi-asserted-by":"crossref","unstructured":"Marchesoni A, Macchioni P, Gasparini S, et al. Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. J Clin Med. 2021;11(1):180. DOI:10.3390\/jcm11010180","DOI":"10.3390\/jcm11010180"},{"key":"10.5826\/dpc.1603a7416_ref35","doi-asserted-by":"crossref","unstructured":"Aaron RV, Ravyts SG, Carnahan ND, et al. Prevalence of Depression and Anxiety Among Adults With Chronic Pain: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2025;8(3):e250268. DOI:10.1001\/jamanetworkopen.2025.0268","DOI":"10.1001\/jamanetworkopen.2025.0268"},{"key":"10.5826\/dpc.1603a7416_ref36","doi-asserted-by":"crossref","unstructured":"Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1481\u20131488. DOI:10.1016\/j.semarthrit.2020.02.001","DOI":"10.1016\/j.semarthrit.2020.02.001"},{"key":"10.5826\/dpc.1603a7416_ref37","doi-asserted-by":"crossref","unstructured":"Merola JF, Wu S, Han J, Choi HK, Qureshi AA. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74(8):1495\u2013500. DOI:10.1136\/annrheumdis-2014-205212","DOI":"10.1136\/annrheumdis-2014-205212"},{"key":"10.5826\/dpc.1603a7416_ref38","doi-asserted-by":"crossref","unstructured":"Marchesoni A, De Marco G, Merashli M, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford). 2018;57(1):32\u201340. DOI:10.1093\/rheumatology\/kex079","DOI":"10.1093\/rheumatology\/kex079"},{"key":"10.5826\/dpc.1603a7416_ref39","doi-asserted-by":"crossref","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1):e004062. DOI:10.1136\/rmdopen-2023-004062","DOI":"10.1136\/rmdopen-2023-004062"},{"key":"10.5826\/dpc.1603a7416_ref40","doi-asserted-by":"crossref","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u2013719. DOI:10.1136\/ard-2024-225531","DOI":"10.1136\/ard-2024-225531"},{"key":"10.5826\/dpc.1603a7416_ref41","doi-asserted-by":"crossref","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1\u201378. DOI:10.23736\/S2784-8671.21.07132-2","DOI":"10.23736\/S2784-8671.21.07132-2"},{"key":"10.5826\/dpc.1603a7416_ref42","doi-asserted-by":"crossref","unstructured":"Shahsavari S, Smith B, Engel P. 43356 Protective E\ufb00ects of Biologics against Psoriatic Arthritis in Patients with Psoriasis. Journal of the American Academy of Dermatology. 2023;89(3):AB77. DOI:10.1016\/j.jaad.2023.07.313","DOI":"10.1016\/j.jaad.2023.07.313"},{"key":"10.5826\/dpc.1603a7416_ref43","doi-asserted-by":"crossref","unstructured":"Joven-Ib\u00e1\u00f1ez B, Rivera R, Hernandez G, Garc\u00eda-Donoso C, Pablos \u00c1lvarez JL. OP0010 EVALUATION OF THE RISK OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS UNDERGOING BIOLOGICAL TREATMENT. GLOBAL POPULATION STUDY (TRINETX). Annals of the Rheumatic Diseases. 2024;83(Suppl 1):168\u2013169. DOI:10.1136\/annrheumdis-2024-eular.5872","DOI":"10.1136\/annrheumdis-2024-eular.5872"},{"key":"10.5826\/dpc.1603a7416_ref44","doi-asserted-by":"crossref","unstructured":"Strober B, Soliman AM, Li C, et al. Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysis. J Am Acad Dermatol. 2024;91(6):1143\u20131149. DOI:10.1016\/j.jaad.2024.06.106","DOI":"10.1016\/j.jaad.2024.06.106"},{"key":"10.5826\/dpc.1603a7416_ref45","doi-asserted-by":"crossref","unstructured":"Jairath V, Acosta Felquer ML, Cho RJ. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024;404(10463):1679\u20131692. DOI:10.1016\/S0140-6736(24)01750-1","DOI":"10.1016\/S0140-6736(24)01750-1"},{"key":"10.5826\/dpc.1603a7416_ref46","doi-asserted-by":"crossref","unstructured":"Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311\u2013325. DOI:10.1038\/s41584-022-00776-6","DOI":"10.1038\/s41584-022-00776-6"},{"key":"10.5826\/dpc.1603a7416_ref47","doi-asserted-by":"crossref","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373. DOI:10.1136\/annrheumdis-2021-219961","DOI":"10.1136\/annrheumdis-2021-219961"},{"key":"10.5826\/dpc.1603a7416_ref48","doi-asserted-by":"crossref","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u201379. DOI:10.1136\/annrheumdis-2021-220865","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"10.5826\/dpc.1603a7416_ref49","doi-asserted-by":"crossref","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study. Arthritis Rheumatol. 2022;74(2):237\u2013243. DOI:10.1002\/art.41946","DOI":"10.1002\/art.41946"},{"key":"10.5826\/dpc.1603a7416_ref50","doi-asserted-by":"crossref","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u2013e207. DOI:10.1016\/S2665-9913(23)00034-6","DOI":"10.1016\/S2665-9913(23)00034-6"},{"key":"10.5826\/dpc.1603a7416_ref51","doi-asserted-by":"crossref","unstructured":"Haberman RH, MacFarlane KA, Catron S, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12):e063650. DOI:10.1136\/bmjopen-2022-063650","DOI":"10.1136\/bmjopen-2022-063650"},{"key":"10.5826\/dpc.1603a7416_ref52","doi-asserted-by":"crossref","unstructured":"Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and Safety of the TYK2\/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol. 2023;75(8):1370\u20131380. DOI:10.1002\/art.42519","DOI":"10.1002\/art.42519"},{"key":"10.5826\/dpc.1603a7416_ref53","doi-asserted-by":"crossref","unstructured":"McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227\u20131239. DOI:10.1056\/NEJMoa2022516","DOI":"10.1056\/NEJMoa2022516"},{"key":"10.5826\/dpc.1603a7416_ref54","doi-asserted-by":"crossref","unstructured":"Ford AR, Siegel M, Bagel J, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatol. 2018;154(8):934\u2013950. DOI:10.1001\/jamadermatol.2018.1412","DOI":"10.1001\/jamadermatol.2018.1412"},{"key":"10.5826\/dpc.1603a7416_ref55","doi-asserted-by":"crossref","unstructured":"Garshick M, Underberg JA. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep. 2017;19(12):48. DOI:10.1007\/s11883-017-0685-7","DOI":"10.1007\/s11883-017-0685-7"},{"key":"10.5826\/dpc.1603a7416_ref56","doi-asserted-by":"crossref","unstructured":"Williams JC, Hum RM, Rogers K, et al. Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis. 2024;16:1759720X241271886. DOI:10.1177\/1759720X241271886","DOI":"10.1177\/1759720X241271886"},{"key":"10.5826\/dpc.1603a7416_ref57","doi-asserted-by":"crossref","unstructured":"Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol. 2024;30(1):26\u201331. DOI:10.1097\/RHU.0000000000001949","DOI":"10.1097\/RHU.0000000000001949"},{"key":"10.5826\/dpc.1603a7416_ref58","doi-asserted-by":"crossref","unstructured":"Abhishek A, Doherty M. Diagnosis and clinical presentation of osteoarthritis. Rheum Dis Clin North Am. 2013;39(1):45\u201366. DOI:10.1016\/j.rdc.2012.10.007","DOI":"10.1016\/j.rdc.2012.10.007"},{"key":"10.5826\/dpc.1603a7416_ref59","doi-asserted-by":"crossref","unstructured":"Marshall M, Watt FE, Vincent TL, Dziedzic K. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol. 2018;14(11):641\u2013656. DOI:10.1038\/s41584-018-0095-4","DOI":"10.1038\/s41584-018-0095-4"},{"key":"10.5826\/dpc.1603a7416_ref60","doi-asserted-by":"crossref","unstructured":"Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4(2):e000656. DOI:10.1136\/rmdopen-2018-000656","DOI":"10.1136\/rmdopen-2018-000656"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/7416\/3900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/7416\/3900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:48Z","timestamp":1785510528000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/7416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1603a7416","relation":{"has-manifestation":[{"id-type":"other","id":"1-84-7416-g3900","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1603a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"2"}}